http://bmj.com/cgi/content/full/323/7323/0
BMJ 2001;323 ( 24 November )
Australians are getting fed up with commercial interests. The Australian
Museum runs prestigious awards for science and science communication,
but its decision to establish a new one for medical journalism sponsored
by Pfizer has provoked opposition from journalists, academics, and
doctors (p 1258).
In describing the row Melissa Sweet says that in the past she has
taken sponsored trips and entered journalism awards. "But no
more. With compelling evidence to show that close ties with industry
can influence doctors' behaviour, there's no reason to expect
journalists would be any different." And it's not just
journalists who are getting sceptical. Australian teachers have been
staying away from workshops sponsored by Philip Morris on
encouraging children to resist drugs, smoking, drinking, and
bullying (p 1206).
David Carvel was also clearly annoyed by a manifestation of commercial
interests. He opened a package delivered to his surgery marked
"urgent"
only
to find an advert for an expensive drug (p 1259).
"I was incensed by this shameless advertising gag and incensed that
I had been duped by it." His complaints got nowhere, but in his
personal view he encourages others to complain
"not
only are drug companies getting more powerful, they are now taking
over the language."
One thing that puzzles researchers is why antithrombotic drugs are
consistently underused in atrial fibrillation, despite clear
evidence of benefit. On p 1218
P J Devereaux and colleagues add to an increasing body of
understanding that doctors and patients differ in their attitudes to
risks. The researchers presented patients at risk of atrial
fibrillation and doctors with scenarios about strokes and bleeding
and asked them to trade off the risks. They found that the minimum
number of strokes that needed to be prevented for warfarin to be
justified was lower (and the number of excess bleeds acceptable
higher) for patients than for doctors. But, importantly, there was
great variability in both groups. So the only answer is to ask
patients what they value when deciding on treatment.
Footnotes
To receive Editor's choice by email each week subscribe via our website: www.bmj.com/cgi/customalert
|
Are randomised controlled trials in the BMJ
different?
Matthias Egger, Christopher
Bartlett, and Peter Jüni
BMJ 2001 323: 1253. [Letter]
NEWS ROUNDUP
Tobacco giant’s antismoking course flops.
Simon Chapman
BMJ 2001 323: 1206.
PAPERS
Differences between perspectives of physicians and patients on
anticoagulation in patients with atrial fibrillation: observational study • Commentary: Varied preferences reflect the
reality of clinical practice.
P J Devereaux, David R Anderson,
Martin J Gardner, Wayne Putnam, Gordon J Flowerdew, Brenda F Brownell, Seema
Nagpal, Jafna L Cox, and Tom Fahey
BMJ 2001 323: 1218.
PRESS
Press: Sponsored journalism award shocks Australian media.
Melissa Sweet
BMJ 2001 323: 1258.
PERSONAL VIEWS
A complaint about drug company advertising.
David Carvel
BMJ 2001 323: 1259.
ALL
INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR
GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE
KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED
AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO
VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU
ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.